ATE395363T1 - Monoklonale antikörper gegen das protein g3bp und deren verwendungen - Google Patents

Monoklonale antikörper gegen das protein g3bp und deren verwendungen

Info

Publication number
ATE395363T1
ATE395363T1 AT99925118T AT99925118T ATE395363T1 AT E395363 T1 ATE395363 T1 AT E395363T1 AT 99925118 T AT99925118 T AT 99925118T AT 99925118 T AT99925118 T AT 99925118T AT E395363 T1 ATE395363 T1 AT E395363T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
g3bp
protein
protein g3bp
concerns
Prior art date
Application number
AT99925118T
Other languages
English (en)
Inventor
Fabienne Parker
Mireille Kenigsberg
Marc Duchesne
Isabelle Barlat
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE395363T1 publication Critical patent/ATE395363T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99925118T 1998-06-17 1999-06-17 Monoklonale antikörper gegen das protein g3bp und deren verwendungen ATE395363T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9807617A FR2780062B1 (fr) 1998-06-17 1998-06-17 Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations

Publications (1)

Publication Number Publication Date
ATE395363T1 true ATE395363T1 (de) 2008-05-15

Family

ID=9527481

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99925118T ATE395363T1 (de) 1998-06-17 1999-06-17 Monoklonale antikörper gegen das protein g3bp und deren verwendungen

Country Status (13)

Country Link
US (1) US7001980B1 (de)
EP (1) EP1087997B1 (de)
JP (1) JP2002518001A (de)
KR (1) KR100694917B1 (de)
CN (1) CN1213070C (de)
AT (1) ATE395363T1 (de)
AU (1) AU764139B2 (de)
CA (1) CA2331151A1 (de)
DE (1) DE69938725D1 (de)
FR (1) FR2780062B1 (de)
HU (1) HUP0103152A3 (de)
IL (2) IL139852A0 (de)
WO (1) WO1999065947A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022779A1 (en) * 2000-06-16 2004-02-05 Thomas Rudel Method for identifying apoptosis-modified proteins
CN1341644A (zh) * 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——人核内非均－核蛋白32.01和编码这种多肽的多核苷酸
AUPR721101A0 (en) * 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
EP1514118A2 (de) * 2002-06-20 2005-03-16 EVOTEC Neurosciences GmbH Diagnostische und therapeutische verwendung von ras-gtpase-aktivierendem sh3-bindendem protein 2 (g3bp2) für neurodegenerative erkrankungen
BRPI0411485A (pt) * 2003-06-30 2006-07-25 Univ Lausanne peptìdeo derivado de rasgap para matar seletivamente células cancerosas
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
JP2013504586A (ja) 2009-09-10 2013-02-07 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 脱ユビキチン化酵素およびユビキチン化ポリペプチドを調節するための方法および材料
CN101921313B (zh) 2010-04-07 2012-02-29 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或其衍生产品及应用
MX2013009859A (es) 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
CN106771258A (zh) * 2017-02-16 2017-05-31 广州赛太特生物医学科技有限公司 一种半乳糖凝集素‑3结合蛋白的检测试剂盒及其方法和应用
EP4062933A4 (de) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antikörperhaltiges präparat
CN115407063A (zh) * 2021-05-26 2022-11-29 江苏科兴诺生物技术有限公司 一种量子点荧光免疫层析法肿瘤标志物（g3bp）试剂盒及其检测方法
CN113755594B (zh) * 2021-09-26 2024-05-14 中国医学科学院肿瘤医院 一种预测小细胞肺癌辅助化疗获益和识别化疗耐药治疗靶点的系统和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5402648A (en) 1993-07-01 1995-04-04 Apd Cryogenics Inc. Sealed dewar with separate circulation loop for external cooling at constant pressure
IL116026A (en) * 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

Also Published As

Publication number Publication date
KR100694917B1 (ko) 2007-03-14
HUP0103152A2 (hu) 2001-12-28
DE69938725D1 (de) 2008-06-26
FR2780062A1 (fr) 1999-12-24
WO1999065947A2 (fr) 1999-12-23
FR2780062B1 (fr) 2000-07-28
EP1087997A2 (de) 2001-04-04
JP2002518001A (ja) 2002-06-25
KR20010052942A (ko) 2001-06-25
AU4151599A (en) 2000-01-05
CN1305497A (zh) 2001-07-25
CA2331151A1 (fr) 1999-12-23
AU764139B2 (en) 2003-08-14
WO1999065947A3 (fr) 2000-02-24
HUP0103152A3 (en) 2004-03-01
EP1087997B1 (de) 2008-05-14
IL139852A (en) 2006-04-10
CN1213070C (zh) 2005-08-03
IL139852A0 (en) 2002-02-10
US7001980B1 (en) 2006-02-21

Similar Documents

Publication Publication Date Title
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
ATE470714T1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
EP1071458A4 (de) Humanisierter antikörper und dessen verwendungen
DE59813875D1 (de) Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EE200000642A (et) Suurendatud saagisega FAPalfa-spetsiifilised antikehad
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ATE362490T1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
DE69728897D1 (de) Saeugetierchemokine
ATE189897T1 (de) Antikörper gegen das prorenin profragment, reninaktive substanz die diese enthält und prorenintest die diese verwendet
DE60042273D1 (de) Antitumorantikörper, proteine und deren verwendung
ATE321768T1 (de) Linker-nucleosid, seine herstellung und verwendung
DE60045637D1 (de) Nicotin-acetylcholin rezeptoruntereinheit, deren isolierung und verwendung
IT1301815B1 (it) Anticorpi monoclonali umani contro l'antigene tumorale uk114 e cellulelinfocitarie e ibridomi per la loro produzione
IT1293510B1 (it) Anticorpi monoclonali catalitici per la trasformazione in vivo di profarmaci di corticosteroidi
DE69836096D1 (de) Anti-idiotypische monoklonale antikörper, deren verwendung zur aktiven immuntherapie bösartiger tumoren, und zusammensetzungen die diese enthalten
WO1999002564A3 (de) Ancrod spezifische monoklonale antikörper, antikörperfragmente, deren mischungen oder derivate und deren verwendung
IT1305309B1 (it) Procedimento per la purificazione di anticorpi anti-tireoglobulina eusi di detti anticorpi.
BR9815776A (pt) Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας
FI956041A7 (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalis ia vasta-aineita CD44V6 vastaan

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties